Mileshkin L - Search Results

1

A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma.

Prince HM, Mileshkin L, Roberts A, Ganju V, Underhill C, Catalano J, Bell R, Seymour JF, Westerman D, Simmons PJ, Lillie K, Milner AD, Iulio JD, Zeldis JB, Ramsay R. Prince HM, et al. Among authors: mileshkin l. Clin Cancer Res. 2005 Aug 1;11(15):5504-14. doi: 10.1158/1078-0432.CCR-05-0213. Clin Cancer Res. 2005. PMID: 16061867 Clinical Trial.

2

Severe interstitial pneumonitis following high-dose cyclophosphamide, thiotepa and docetaxel: two case reports and a review of the literature.

Mileshkin L, Prince HM, Rischin D, Zimet A. Mileshkin L, et al. Bone Marrow Transplant. 2001 Mar;27(5):559-63. doi: 10.1038/sj.bmt.1702803. Bone Marrow Transplant. 2001. PMID: 11313694 Review.

3

Successful treatment of rhinocerebral zygomycosis using liposomal nystatin.

Mileshkin L, Slavin M, Seymour JF, McKenzie A. Mileshkin L, et al. Leuk Lymphoma. 2001 Sep-Oct;42(5):1119-23. doi: 10.3109/10428190109097734. Leuk Lymphoma. 2001. PMID: 11697631

4

Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation.

Biagi JJ, Mileshkin L, Grigg AP, Westerman DW, Prince HM. Biagi JJ, et al. Among authors: mileshkin l. Bone Marrow Transplant. 2001 Dec;28(12):1145-50. doi: 10.1038/sj.bmt.1703292. Bone Marrow Transplant. 2001. PMID: 11803357

5

Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.

Mileshkin L, Biagi JJ, Mitchell P, Underhill C, Grigg A, Bell R, McKendrick J, Briggs P, Seymour JF, Lillie K, Smith JG, Zeldis JB, Prince HM. Mileshkin L, et al. Blood. 2003 Jul 1;102(1):69-77. doi: 10.1182/blood-2002-09-2846. Epub 2003 Mar 13. Blood. 2003. PMID: 12637329 Free article. Clinical Trial.

6

Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide.

Mileshkin L, Prince HM, Seymour JF, Biagi JJ. Mileshkin L, et al. Br J Haematol. 2003 Nov;123(4):747-8; author reply 748. doi: 10.1046/j.1365-2141.2003.04677.x. Br J Haematol. 2003. PMID: 14616984 Free article. No abstract available.

7

A comparison of fluorine-18 fluoro-deoxyglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma.

Mileshkin L, Blum R, Seymour JF, Patrikeos A, Hicks RJ, Prince HM. Mileshkin L, et al. Eur J Haematol. 2004 Jan;72(1):32-7. doi: 10.1046/j.0902-4441.2004.00177.x. Eur J Haematol. 2004. PMID: 14962260

8

An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital.

Worth LJ, Dooley MJ, Seymour JF, Mileshkin L, Slavin MA, Thursky KA. Worth LJ, et al. Among authors: mileshkin l. Br J Cancer. 2005 Mar 14;92(5):867-72. doi: 10.1038/sj.bjc.6602412. Br J Cancer. 2005. PMID: 15726101 Free PMC article. Clinical Trial.

9

The contribution of cytotoxic chemotherapy to the management of cancer.

Mileshkin L, Rischin D, Prince HM, Zalcberg J. Mileshkin L, et al. Clin Oncol (R Coll Radiol). 2005 Jun;17(4):294. doi: 10.1016/j.clon.2005.02.012. Clin Oncol (R Coll Radiol). 2005. PMID: 15997929 No abstract available.

10

The adverse prognostic impact of advanced age in multiple myeloma.

Mileshkin L, Prince HM. Mileshkin L, et al. Leuk Lymphoma. 2005 Jul;46(7):951-66. doi: 10.1080/10428190500085024. Leuk Lymphoma. 2005. PMID: 16019546 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

294 results

Search Page

Filters